Bejel serology behaves like syphilis after treatment in Japanese cohort
A small but clinically consequential PLOS Medicine study shows that bejel, caused by Treponema pallidum subsp. endemicum, produces post-treatment serologic changes that closely resemble those seen in syphilis. In six genetically confirmed bejel cases and nine syphilis cases treated in Japan, treponemal and nontreponemal antibody titers moved in parallel after therapy when measured with latex-based immunoassays. The finding matters because bejel has traditionally been framed as a nonvenereal treponematosis of arid regions, yet sexually transmitted infections due to this organism are now being documented outside endemic settings.
The biological question is straightforward: if the organism is a close treponemal relative of the syphilis pathogen, can standard syphilis serology still function as a practical monitoring tool? These data point to yes. Even though the infections differ in epidemiology and classic transmission routes, the humoral immune response appears similar enough that conventional assays can be used to follow treatment response rather than requiring a separate diagnostic framework for every treponemal subspecies.
Treponemal and nontreponemal titers moved in parallel
Investigators quantified serum treponemal (TP) and nontreponemal (RPR) antibody titers at baseline and after treatment using latex agglutination testing. They also examined antibody profiles with an immunoblot assay that detected IgM and IgG responses against Tp47, TmpA, Tp17, and Tp15. Phylogenetic analysis based on concatenated tp0548 and tp0856 sequences identified the six bejel infections as TEN, confirming that this was not a clinical guess based on serology alone.
The serologic pattern was not dramatic in the sense of diverging sharply between groups. It was more clinically useful than dramatic. In both bejel and syphilis, treatment was followed by broadly similar changes in TP and RPR titers, and the two infections could not be cleanly separated by the direction of serologic response after therapy.
A single sentence captures the operational takeaway: standard syphilis serology did not misbehave in bejel.
IgM fell, IgG sometimes rose, and the immune signature stayed familiar
The immunoblot results add nuance to the overall serologic picture. Some IgM antibodies decreased after treatment in both groups, while some IgG antibodies increased. That combination is consistent with an immune response that is evolving rather than collapsing in a binary on-off fashion. In treponemal disease, antibody kinetics often lag behind microbial clearance, and the persistence or rise of specific IgG signals can reflect the immune system’s longer memory rather than ongoing viable infection.
Those antibody shifts are important because clinicians often want a simple marker for cure. Treponemal tests are excellent for diagnosis but are notoriously limited as a short-term gauge of therapeutic success, while nontreponemal titers are more dynamic and commonly used for follow-up. The bejel data suggest that the same laboratory logic can extend to this neglected treponemal infection, even when the organism is not Treponema pallidum subsp. pallidum.
The study did not identify a distinctive post-treatment serologic signature that would force a new monitoring paradigm for bejel.
Why this matters outside endemic regions
Bejel has long been associated with children and adolescents in arid regions, spread through close contact or shared utensils. Yet recent reports have identified sexually transmitted cases among men who have sex with men in France, Cuba, and Japan. When a pathogen migrates into a different transmission network, the clinical challenge shifts. Physicians cannot depend on old epidemiology alone, and laboratory tests built for one treponemal disease suddenly need to perform in another.
Japan has already seen repeated identification of bejel in patients initially evaluated as having syphilis. The broader implication is not that syphilis testing is imperfect, but that it may be unexpectedly useful. If the same serologic tools track treatment response in both diseases, then routine follow-up of suspected bejel can remain anchored to existing laboratory infrastructure. That is particularly valuable in non-endemic settings, where separate assays for a rare treponematosis would be hard to justify.
Molecular confirmation sharpened the interpretation
The inclusion of phylogenetic analysis gives the findings their strongest scientific footing. Because treponemal subspecies share high nucleotide identity, serology alone cannot distinguish them reliably. Molecular typing based on tp0548 and tp0856 allowed the investigators to confirm the bejel cases and compare them with syphilis on firmer ground. Without that step, similar antibody behavior could have been dismissed as a nonspecific feature of treponemal infection in general. With it, the study supports a more specific conclusion: the serologic response to treatment in TEN looks clinically comparable to that seen in TPA infection.
The result is especially relevant because clinicians in non-endemic areas may encounter patients whose sexual history or travel history does not fit classic bejel teaching. When molecular diagnostics are available, they can define the organism. When they are not, serology still appears to provide a workable way to monitor response after treatment.
A narrow evidence base, but a practical signal
The study remains small, with six genetically confirmed bejel cases and nine syphilis cases, so it cannot settle every question about treponemal immunology. It also does not replace molecular diagnosis when organism-level confirmation is needed. What it does show is more immediate: conventional treponemal and nontreponemal assays, including latex-based immunoassays, behaved similarly in both infections after treatment, and the antibody patterns were compatible with standard clinical follow-up.
For bedside care, that means a patient with confirmed or suspected bejel does not automatically require a separate post-treatment serologic playbook. For public health teams, it suggests that emerging sexually transmitted bejel in non-endemic settings can be tracked with the same tools already used for syphilis surveillance and follow-up. The remaining question is not whether serology is usable, but how often clinicians outside endemic regions will recognize bejel early enough to test for it in the first place.